$Regencell Bioscience(RGC.US) dropped -21% in a single day. The previous short-squeeze style impulse is receding, with profit-taking concentrated for settlement.
It's still shadowed by securities litigation and a DOJ subpoena, and the company itself has no actual revenue to support it, with valuation purely driven by sentiment. For a target like this without a fundamental foundation, the decline is often more decisive than the rise, and any rebound is likely just a one-time correction of oversold sentiment.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
